Fundraising Fox

Arch Therapeutics

Wellesley, US · Founded 2009 · Nevada corporation

Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.

BiotechMedical Devices

Founders & leadership

Arch Therapeutics was founded in 2009 by Terrence Norchi and Norchi Terrence.

TN
Terrence NorchiCo-founder
NT
Norchi TerrenceCo-founder
WC
William CotterExecutive
RD
Richard DavisExecutive
AB
Alan BarberExecutive

Board

AD
Avtar DhillonBoard director
AR
Arthur RosenthalBoard director

Reported raises · per SEC filings

Form D private placements

$18.7M disclosed across 6 rounds · 2014–2022

▶$4.2MraisedJul 2022 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Guy FishDirector
  • Laurence HicksDirector
  • Daniel M. YrigoyenExecutive Officer
  • Terrence W. NorchiExecutive Officer, Director
  • Punit DhillonDirector
  • Michael S. AbramsExecutive Officer
Offering amount
$4.2M
Amount sold
$4.2M
Sales commissions
$240K
Placement agents
Maxim Group LLP
First sale
Jul 2022
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.9MraisedFeb 2021 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • Richard E. DavisExecutive Officer
  • James R. SulatDirector
  • Punit DhillonDirector
Offering amount
$7.5M
Amount sold
$6.9M
Sales commissions
$492.8K
Placement agents
H.C. Wainwright & Co.
First sale
Feb 2021
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$550KraisedJun 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • Richard E. DavisExecutive Officer
  • Punit DhillonDirector
  • James R. SulatDirector
Offering amount
$2M
Amount sold
$550K
First sale
Jun 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedJun 2016 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • James R. SulatDirector
  • Avtar DhillonDirector
  • Richard E. DavisExecutive Officer
Offering amount
$3.5M
Amount sold
$3.4M
Sales commissions
$171K
Placement agents
MAXIM GROUP LLC
First sale
May 2016
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750KraisedMar 2015 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William CotterExecutive Officer
  • Terrence NorchiExecutive Officer, Director
  • Richard DavisExecutive Officer
  • Avtar DhillonDirector
  • Arthur RosenthalDirector
Offering amount
$750K
Amount sold
$750K
First sale
Mar 2015
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedFeb 2014 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Avtar DhillonDirector
  • William CotterExecutive Officer
  • Norchi TerrenceExecutive Officer, Director
  • Arthur RosenthalDirector
  • Alan BarberExecutive Officer
Offering amount
$2.9M
Amount sold
$2.9M
First sale
Feb 2014
Incorporated
Corporation, Nevada, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
StockTwits7 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies competing with Arch Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Arch Therapeutics and Interpace Biosciences Face Off in Volatility and Valuation - Framingham Todaynationaltoday.com · Apr 2026Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financingglobenewswire.com · Jul 2022Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Repriceglobenewswire.com · Jun 2020Arch Raises $1.4 Million with Convertible Note Issuance and Warrant RepriceFinancing with long-term shareholders provides flexibility during product roll-out - BioSpacebiospace.com · Jun 2020Arch Therapeutics raises $3M in financingwbjournal.com · Jul 2015Arch, a wound care device startup, raises $7.3M | Fierce Biotechfiercebiotech.com · Jul 2013

Frequently asked questions

What does Arch Therapeutics do?
Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.
Who founded Arch Therapeutics?
Arch Therapeutics was founded by Terrence Norchi, Norchi Terrence in 2009.
How much funding has Arch Therapeutics raised?
Arch Therapeutics has disclosed $18.7M raised across 6 rounds.
Where is Arch Therapeutics headquartered?
Arch Therapeutics is headquartered in Wellesley, US.